Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 11/21/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. David B. Karpf MD

Wrong Dr. David B. Karpf MD?

Chief Medical Officer

Virobay Inc
1360 Willow Road, Suite 100
Menlo Park , California 94025
United States

Company Description: At Virobay we are developing protease inhibitors for the treatment of autoimmune diseases, neuropathic pain, liver diseases and cancer. Our virtual model of drug...   more

Employment History


  • MD
  • M.D.
    University of California , San Diego
  • B.A. , Psychology and Biology
    University of California , Berkeley
  • M.D. degree
    University of California , San Diego
68 Total References
Web References
ViroBay, 21 Nov 2014 [cached]
David B. Karpf MD Chief Medical Officer
David B. Karpf MD Chief Medical Officer
David B. Karpf, M.D. has served as our Chief Medical Officer since October 2011. From December 2010 to October 2011, Dr. Karpf served as a life sciences consultant. From January 2004 to December 2010, Dr. Karpf served as Chief Medical Officer and Vice President of Clinical Affairs at Metabolex, Inc., now CymaBay Therapeutics, Inc., where he oversaw the development of clinical programs in various diseases, including type 2 diabetes, gout and dyslipdemia. From May 2001 to January 2004, Dr. Karpf served as Executive Director of Clinical Research and Regulatory Affairs at Geron Corporation, or Geron, a clinical stage biopharmaceutical company, where he oversaw early clinical programs in cancer and regenerative medicine. From May 2000 to May 2001, Dr. Karpf served as Vice President, Clinical and Regulatory Affairs at Calydon, Inc., a company that developed oncolytic virus cancer treatments, which was acquired by Cell Genesis, Inc. in September 2001. From October 1996 to May 2000, Dr. Karpf served as Executive Director of Clinical Research at Roche, where he was responsible for clinical development activities in endocrinology and metabolic bone disease. From August 1991 to December 1996, Dr. Karpf served as Director of Clinical Research at Merck Research Laboratories, where he played a pivotal role in the successful New Drug Application and launch of Fosamax™. Dr. Karpf has also held several academic positions and is currently an adjunct clinical professor of endocrinology at Stanford University School of Medicine. Dr. Karpf received a B.A. in Psychology and Biology from University of California, Berkeley and an M.D. from University of California, San Diego. He completed a residency in Internal Medicine and a fellowship in Endocrinology, Diabetes and Metabolism at University of California, Los Angeles School of Medicine and Cedars-Sinai Medical Center, and a post-doctoral fellowship in the Endocrine Unit at University of California, San Francisco School of Medicine.
Metabolex, Inc., 21 July 2010 [cached]
David B. Karpf
David B. Karpf, M.D. Chief Medical Officer
Dr. Karpf joined Metabolex in 2004 as Chief Medical Officer and Vice President, Clinical and Regulatory Affairs. He previously was at Geron Corporation, where he served as executive medical director, clinical and regulatory affairs from 2001. Prior to Geron, Dr. Karpf was vice president, clinical and regulatory affairs at Calydon, Inc. and executive director of clinical research at Roche Global Development in Palo Alto. From 1991 to 1996, Dr. Karpf was director of clinical research at Merck Research Laboratories in Rahway, New Jersey. Dr. Karpf is currently a clinical professor with the Stanford University School of Medicine. He received his M.D. degree from University of California, San Diego.
In The News, 4 June 2008 [cached]
Dr. David B. Karpf, Chief Medical Officer of Metabolex and Clinical Associate Professor of Medicine at Stanford University School of Medicine, stated that to have a drug that addresses insulin resistance without causing the typically observed side effects of weight gain and edema, which should also predict a lower risk of congestive heart failure, would be a significant advance in the treatment of this common and often debilitating disease.
Medical & Scientific Advisory Board, 6 May 2014 [cached]
David Karpf picture
David Karpf, MD, President, Medical and Scientific Advisory
Dr. Karpf is an adjunct clinical professor of endocrinology at Stanford University School of Medicine, where he sees patients with osteoporosis and metabolic bone disease. He is board certified in internal medicine with a subspecialty in endocrinology and metabolism. A UC Berkeley graduate, Dr. Karpf received his medical degree from UC San Diego and completed residency in internal medicine and fellowship in endocrinology, diabetes and metabolism at UCLA/Cedars-Sinai Medical Center. This was followed by a fellowship in metabolic bone disease in the endocrine bone unit at UCSF, where his bench research focused on characterization and isolation of the PTH/PTHrP receptor.
3. Virobay Appoints ..., 10 Nov 2011 [cached]
3. Virobay Appoints David B. Karpf, M.D. as Chief Medicial Officer
Other People with the name "Karpf":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.